Paul M. Mathews

Paul M. Mathews

Auto-generated profile, based on publicly available information

Paul M. Mathews

Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2000 in Nature
Verified
Journal Article
Closed access
PDF file
CJChristopher Janus
Christopher Janus
JPJacqueline Pearson
Jacqueline Pearson
JMJoAnne McLaurin
JoAnne McLaurin
PMPaul M. Mathews
Paul M. Mathews
YJYing Jiang
Ying Jiang
DWDavid Westaway
David Westaway

11 August 2006 in EMBO Reports
Verified
Journal Article
Open access
PDF file
RRRebecca Radde
Rebecca Radde
TBTristan Bolmont
Tristan Bolmont
SKStephan A Kaeser
Stephan A Kaeser
JCJanaky Coomaraswamy
Janaky Coomaraswamy
DLDennis Lindau
Dennis Lindau
MJMathias Jucker
Mathias Jucker
We have generated a novel transgenic mouse model on a C57BL/6J genetic background that coexpresses KM670/671NL mutated amyloid precursor protein and L166P mutated presenilin 1 under the control of a neuron‐specific Thy1 promoter element (APPPS1 mice). Cerebral amyloidosis starts at 6–8 weeks and the ratio of human amyloid (A)β42 to Aβ40 is 1.5 and 5 in pre‐depositing and amyloid‐depositing mice, respectively. Consistent with this ratio, extensive congophilic parenchymal amyloid but minimal amyloid angiopathy is observed. Amyloid‐associated pathologies include dystrophic synaptic boutons, hyperphosphorylated tau‐positive neuritic structures and robust gliosis, with neocortical microglia number increasing threefold from 1 to 8 months of age. Global neocortical neuron loss is not apparent up to 8 months of age, but local neuron loss in the dentate gyrus is observed. Because of the early onset of amyloid lesions, the defined genetic background of the model and the facile breeding characteristics, APPPS1 mice are well suited for studying therapeutic strategies and the pathomechanism of amyloidosis by cross‐breeding to other genetically engineered mouse models.

22 September 2006 in Science
Verified
Journal Article
Closed access
PDF file
MMMelanie Meyer-Luehmann
Melanie Meyer-Luehmann
JCJanaky Coomaraswamy
Janaky Coomaraswamy
TBTristan Bolmont
Tristan Bolmont
SKStephan Kaeser
Stephan Kaeser
CSClaudia Schaefer
Claudia Schaefer
MJMathias Jucker
Mathias Jucker
Protein aggregation is an established pathogenic mechanism in Alzheimer's disease, but little is known about the initiation of this process in vivo. Intracerebral injection of dilute, amyloid-β (Aβ)–containing brain extracts from humans with Alzheimer's disease or β-amyloid precursor protein (APP) transgenic mice induced cerebral β-amyloidosis and associated pathology in APP transgenic mice in a time- and concentration-dependent manner. The seeding activity of brain extracts was reduced or abolished by Aβ immunodepletion, protein denaturation, or by Aβ immunization of the host. The phenotype of the exogenously induced amyloidosis depended on both the host and the source of the agent, suggesting the existence of polymorphic Aβ strains with varying biological activities reminiscent of prion strains.

3 October 2005 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
WYW. Haung Yu
W. Haung Yu
ACAna Maria Cuervo
Ana Maria Cuervo
AKAsok Kumar
Asok Kumar
CPCorrinne M. Peterhoff
Corrinne M. Peterhoff
SSStephen D. Schmidt
Stephen D. Schmidt
RNRalph A. Nixon
Ralph A. Nixon
Macroautophagy, which is a lysosomal pathway for the turnover of organelles and long-lived proteins, is a key determinant of cell survival and longevity. In this study, we show that neuronal macroautophagy is induced early in Alzheimer's disease (AD) and before β-amyloid (Aβ) deposits extracellularly in the presenilin (PS) 1/Aβ precursor protein (APP) mouse model of β-amyloidosis. Subsequently, autophagosomes and late autophagic vacuoles (AVs) accumulate markedly in dystrophic dendrites, implying an impaired maturation of AVs to lysosomes. Immunolabeling identifies AVs in the brain as a major reservoir of intracellular Aβ. Purified AVs contain APP and β-cleaved APP and are highly enriched in PS1, nicastrin, and PS-dependent γ-secretase activity. Inducing or inhibiting macroautophagy in neuronal and nonneuronal cells by modulating mammalian target of rapamycin kinase elicits parallel changes in AV proliferation and Aβ production. Our results, therefore, link β-amyloidogenic and cell survival pathways through macroautophagy, which is activated and is abnormal in AD.

15 November 2002 in Science
Verified
Journal Article
Closed access
PDF file
MPM. Pfeifer
M. Pfeifer
SBS. Boncristiano
S. Boncristiano
LBL. Bondolfi
L. Bondolfi
ASA. Stalder
A. Stalder
TDT. Deller
T. Deller
MJM. Jucker
M. Jucker

22 December 2010 in Brain
Verified
Journal Article
Open access
PDF file
DYDun-Sheng Yang
Dun-Sheng Yang
PSPhilip Stavrides
Philip Stavrides
PMPanaiyur S. Mohan
Panaiyur S. Mohan
SKSusmita Kaushik
Susmita Kaushik
AKAsok Kumar
Asok Kumar
RNRalph A. Nixon
Ralph A. Nixon
Autophagy, a major degradative pathway for proteins and organelles, is essential for survival of mature neurons. Extensive autophagic-lysosomal pathology in Alzheimer’s disease brain contributes to Alzheimer’s disease pathogenesis, although the underlying mechanisms are not well understood. Here, we identified and characterized marked intraneuronal amyloid-β peptide/amyloid and lysosomal system pathology in the Alzheimer’s disease mouse model TgCRND8 similar to that previously described in Alzheimer’s disease brains. We further establish that the basis for these pathologies involves defective proteolytic clearance of neuronal autophagic substrates including amyloid-β peptide. To establish the pathogenic significance of these abnormalities, we enhanced lysosomal cathepsin activities and rates of autophagic protein turnover in TgCRND8 mice by genetically deleting cystatin B, an endogenous inhibitor of lysosomal cysteine proteases. Cystatin B deletion rescued autophagic-lysosomal pathology, reduced abnormal accumulations of amyloid-β peptide, ubiquitinated proteins and other autophagic substrates within autolysosomes/lysosomes and reduced intraneuronal amyloid-β peptide. The amelioration of lysosomal function in TgCRND8 markedly decreased extracellular amyloid deposition and total brain amyloid-β peptide 40 and 42 levels, and prevented the development of deficits of learning and memory in fear conditioning and olfactory habituation tests. Our findings support the pathogenic significance of autophagic-lysosomal dysfunction in Alzheimer’s disease and indicate the potential value of restoring normal autophagy as an innovative therapeutic strategy for Alzheimer’s disease.